45.31
前日終値:
$45.38
開ける:
$45.68
24時間の取引高:
1.17M
Relative Volume:
0.45
時価総額:
$9.36B
収益:
$2.10B
当期純損益:
$402.17M
株価収益率:
23.41
EPS:
1.9357
ネットキャッシュフロー:
$403.87M
1週間 パフォーマンス:
-1.05%
1か月 パフォーマンス:
+6.61%
6か月 パフォーマンス:
+10.81%
1年 パフォーマンス:
-3.29%
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, NTRA, A, IQV
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
QGEN
Qiagen Nv
|
45.31 | 9.36B | 2.10B | 402.17M | 403.87M | 1.9357 |
|
TMO
Thermo Fisher Scientific Inc
|
662.24 | 244.86B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
221.20 | 155.50B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
397.77 | 57.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
171.33 | 48.30B | 7.23B | 1.41B | 1.09B | 4.979 |
|
IQV
Iqvia Holdings Inc
|
262.21 | 43.16B | 16.63B | 1.39B | 2.12B | 8.0674 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2026-09-09 | 再開されました | UBS | Neutral |
| 2026-07-14 | ダウングレード | Berenberg | Buy → Hold |
| 2026-06-25 | 開始されました | Kepler | Hold |
| 2026-06-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2026-04-29 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2026-04-14 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2026-03-13 | アップグレード | Deutsche Bank | Hold → Buy |
| 2026-01-22 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-06-24 | 開始されました | Barclays | Overweight |
| 2025-04-04 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | アップグレード | Jefferies | Hold → Buy |
| 2024-10-17 | ダウングレード | HSBC Securities | Buy → Hold |
| 2024-06-27 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-07 | アップグレード | Goldman | Neutral → Buy |
| 2023-09-12 | 開始されました | Robert W. Baird | Outperform |
| 2023-05-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-01-18 | アップグレード | DZ Bank | Hold → Buy |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-10-14 | 開始されました | Redburn | Buy |
| 2021-07-14 | ダウングレード | Kepler | Buy → Hold |
| 2021-06-03 | 開始されました | Goldman | Neutral |
| 2020-10-06 | 再開されました | BofA Securities | Buy |
| 2020-09-28 | アップグレード | Kepler | Hold → Buy |
| 2020-08-24 | アップグレード | Citigroup | Neutral → Buy |
| 2020-08-20 | 再開されました | JP Morgan | Overweight |
| 2020-08-17 | アップグレード | Berenberg | Hold → Buy |
| 2020-08-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2020-08-14 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | ダウングレード | Berenberg | Buy → Hold |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Neutral |
| 2019-12-26 | 再開されました | BofA/Merrill | Underperform |
| 2019-11-15 | 開始されました | Stifel | Hold |
| 2019-11-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-11-14 | アップグレード | JP Morgan | Underweight → Overweight |
| 2019-11-14 | アップグレード | Kepler | Reduce → Hold |
| 2019-10-17 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | ダウングレード | Kepler | Hold → Reduce |
| 2019-10-08 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-10-08 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Qiagen Nv (QGEN) 最新ニュース
Qiagen stock gains 0.39 percent after-hours to EUR 40.74 - AD HOC NEWS
Qiagen stock gets a new AI growth story from QIAGEN - AD HOC NEWS
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA): BlackRock Notifies 13.04% Voting Rights - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Discloses BlackRock 12.90% Voting Rights - TradingView
QIAGEN N.V. (QIA) Notes AFM Disclosure on BlackRock Voting Rights - TradingView
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - Business Wire
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
Qiagen NV (CEUX:QIAD) Shiller PE Ratio : (As of Oct. 03, 2026) - GuruFocus
QIAGEN N.V. (QIA): Bank of America Holds 4.95% Voting Rights - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) AFM Discloses Bank of America Voting Rights Notice - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN jumps as new FDA clearance bolsters its syndromic-testing growth story - Quiver Quantitative
Qiagen (NYSE:QGEN) Shares Climb 7.7%What's Next? - MarketBeat
Qiagen gains on report talks with potential buyer have advanced (QGEN:NYSE) - Seeking Alpha
Qiagen N.V. (1QGEN.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel - Yahoo Finance UK
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel - TradingView
A Look at Qiagen NV (QGEN) After 3.9% Decline -- GF Value $49.92 vs Price $42.04 - GuruFocus
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
QIAGEN N.V. (QIA) Notified of Bank of America Voting Rights Filing - TradingView
QIAGEN N.V. (QIA): Bank of America Discloses 5.15% Holding - TradingView
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Notes AFM Filing on Voting Rights Change - TradingView
QIAGEN N.V. (QIA): Bank of America At 5.15% Stake - TradingView
QIAGEN N.V. (QIA) Discloses BlackRock Voting Rights Notification - TradingView
QIAGEN N.V. (QIA): BlackRock Holds 12.97% Voting Rights - TradingView
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM BlackRock Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Reports AFM BlackRock Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Notes AFM Voting Rights Notice by BlackRock - TradingView
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel - BioBuzz
Qiagen NV (CEUX:QIAD) Cyclically Adjusted PB Ratio : (As of Sep. 29, 2026) - GuruFocus
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Preliminary Q1 2026 Qiagen NV Earnings Call Transcript - GuruFocus
Qiagen grounds drug discovery agents in curated knowledge - SiliconANGLE
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
QIAGEN says FDA cleared second QIAstat‑Dx bloodstream panel - Mugglehead Investment Magazine
A new infection test finds 13 bacteria and 18 signs of antibiotic resistance in about an hour. - Stock Titan
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51 - MarketBeat
Warren Wise decodes Qiagen’s DNA - TradingView
Qiagen Nv (QGEN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):